Rho kinase inhibitors
A compound represented by the formula (1): wherein R 1 —X— indicates that 1 to 4 R 1 —X— groups are present which may be the same or different, the ring A is a saturated or unsaturated 5-membered heterocyclic ring, X is a single bond, a group represented by the formula: —N(R 3 )—, —O— or —S—, or the like. R 1 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, R 2 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, and R 3 is a hydrogen atom, a substituted or unsubstituted alkyl group, or the like; a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is a useful compound as a therapeutic agent for diseases for which Rho kinase is responsible.
1. A method of treating disease through inhibiting Rho kinase, wherein the disease is selected from the group consisting of hypertension, angina, cerebral vasospasm, asthma, prostatic hypertrophy, blood vessel restinosis, cardiac hypertrophy, glaucoma, erectile dysfunction, and urinary incontinence, said method comprising administering a therapeutically effective amount of a compound represented by the formula (5):
wherein the groups represented by the formulas R 1a and X a are as follows:
(i) R 1a is a substituted or unsubstituted alkyl group and X a is a single bond, or
(ii) R 1a is a carboxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted alkoxycarbonyl group, a substituted or unsubstituted alkylsulfonyl group, a substituted or unsubstituted arylsulfonyl group, or a cycloalkyl group substituted by a substituted or unsubstituted alkyl group, and X a is a group represented by the formula: —O—, —C(═O)N(R 3 )—, —S(O) n —, —S(O) 2 N(R 3 )— or —C(═O)—
R 1b is a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted cycloalkenyl group;
X b is a group represented by the formula: —O—, —N(R 3 )—, —NHC(═O)—, or —C(═O)NH—,
both of the groups represented by the formulas R 1c -X c and R 1d -X d are hydrogen atoms,
provided that when R 1a is an unsubstituted alkyl group, the corresponding X a is not the group represented by the formula: —C(═O)—;
R 3 is a hydrogen atom, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, or an unsubstituted arylalkyl group,
R 51 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, an unsubstituted alkoxycarbonyl group, or a group represented by the formula: —OR 8 , —N(R 9 )R 10 , —CON(R 9 )R 10 , —SO 2 N(R 9 )R 10 or —S(O) m R 11 ,
m is 0, 1 or 2,
each of R 8 , R 9 and R 10 , which may be the same or different, is a hydrogen atom, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, an unsubstituted alkoxycarbonyl group, or an unsubstituted arylalkyl group,
R 11 is an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, or an unsubstituted arylalkyl group, and
R 6 is a hydrogen atom, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, an unsubstituted alkoxycarbonyl group, or a group represented by the formula: —CON(R 9 )R 10 , —SO 2 N(R 9 )R 10 or —S(O) mR 11 ;
a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.
2. A compound represented by the formula (5):
wherein the groups represented by the formulas R 1a and X a are as follows:
(i) R 1a is a substituted or unsubstituted alkyl group and X a is a single bond, or
(ii) R 1a is a carboxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted alkoxycarbonyl group, a substituted or unsubstituted alkylsulfonyl group, a substituted or unsubstituted arylsulfonyl group, or a cycloalkyl group substituted by a substituted or unsubstituted alkyl group, and X a is a group represented by the formula: —O—, —C(═O)N(R 3 )—, —S(O) n —, —S(O) 2 N(R 3 )— or —C(═O)—
R 1b is a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted cycloalkenyl group;
X b is a group represented by the formula: —O—, —N(R 3 )—, —NHC(═O)—, or —C(═O)NH—,
both of the groups represented by the formulas R 1c —X c and R 1d —X d are hydrogen atoms, provided that when Ria is an unsubstituted alkyl group, the corresponding Xa is not the group represented by the formula: —C(═O)—;
R 3 is a hydrogen atom, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, or an unsubstituted arylalkyl group,
R 51 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, an unsubstituted alkoxycarbonyl group, or a group represented by the formula: —OR 8 , —N(R 9 )R 10 , CON(R 9 )R 10 , —SO 2 N(R 9 )R 10 or —S(O) m R 11 ,
m is 0, 1 or 2,
each of R 8 , R 9 and R 10 , which may be the same or different, is a hydrogen atom, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, an unsubstituted alkoxycarbonyl group, or an unsubstituted arylalkyl group,
R 11 is an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, or an unsubstituted arylalkyl group, and
R 6 is a hydrogen atom, an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted cycloalkenyl group, an unsubstituted alkoxycarbonyl group, or a group represented by the formula: —CON(R 9 )R 10 , —SO 2 N(R 9 )R 10 or —S(O) mR 11 ;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
3. A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 2 , wherein the group represented by X a is a group represented by the formula: —O—.
4. A pharmaceutical composition comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to any one of claims 2 to 3 .
5. A compound according to claim 2 , wherein R 51 and R 6 are hydrogen atoms;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
6. A compound according to claim 2 , wherein R 1b is a substituted cycloalkyl group and X b is a group represented by the formula: —O—;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
7. A compound according to claim 2 , wherein R 1a is a substituted or unsubstituted alkyl group and X a is a single bond or a group represented by the formula: —O— or —S—;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
8. A compound according to claim 2 , wherein R 51 and R 6 are hydrogen atoms;
R 1b is a substituted cycloalkyl group;
and X b is a group represented by the formula: —O—;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
9. A compound according to claim 2 , wherein R 51 and R 6 are hydrogen atoms;
R 1a is a substituted or unsubstituted alkyl group;
and X a is a single bond or a group represented by the formula: —O— or —S—;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
10. A compound according to claim 2 , wherein R 1b is a substituted cycloalkyl group;
X b is a group represented by the formula: —O—;
R 1a is a substituted or unsubstituted alkyl group;
and X a is a single bond or a group represented by the formula: —O— or —S—;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
11. A compound according to claim 2 , wherein R 1b is a substituted cycloalkyl group;
R 1b is a substituted cycloalkyl group;
X b is a group represented by the formula: —O—;
R 1a is a substituted or unsubstituted alkyl group;
and X a is a single bond or a group represented by the formula: —O— or —S—;
a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.
12. A method of treating disease through inhibiting Rho kinase according to claim 1 , wherein the disease is urinary incontinence.